• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用瑞德西韦和中和抗体鸡尾酒治疗 X 连锁无丙种球蛋白血症患者的 SARS-CoV-2 复发。

Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia.

机构信息

Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; Centre for Multidisciplinary Research in Health Science, University of Milan, Milan, Italy.

Department of Internal Medicine, Rare Diseases Unit, Primary Immunodeficiencies Centre for Adults, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

出版信息

Int J Infect Dis. 2021 Sep;110:338-340. doi: 10.1016/j.ijid.2021.07.064. Epub 2021 Jul 28.

DOI:10.1016/j.ijid.2021.07.064
PMID:34332085
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8317455/
Abstract

During the coronavirus disease 2019 (COVID-19) pandemic, patients with humoral immunodeficiency are at higher risk of developing chronic infection and having a negative outcome. Few data are available on therapeutic options for this population. This case report discusses the treatment of disease relapse with remdesivir and monoclonal antibodies in an adult patient with X-linked agammaglobulinaemia.

摘要

在 2019 年冠状病毒病（COVID-19）大流行期间，体液免疫缺陷的患者发生慢性感染和不良结局的风险更高。针对该人群的治疗选择的数据有限。本病例报告讨论了用瑞德西韦和单克隆抗体治疗 X 连锁无丙种球蛋白血症成年患者疾病复发的情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca13/8317455/218f6743f662/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca13/8317455/218f6743f662/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca13/8317455/218f6743f662/gr1_lrg.jpg

相似文献

1
Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia.用瑞德西韦和中和抗体鸡尾酒治疗 X 连锁无丙种球蛋白血症患者的 SARS-CoV-2 复发。
Int J Infect Dis. 2021 Sep;110:338-340. doi: 10.1016/j.ijid.2021.07.064. Epub 2021 Jul 28.
2
SARS-CoV-2 Infection in an Adolescent With X-linked Agammaglobulinemia.SARS-CoV-2 感染伴 X 连锁无丙种球蛋白血症的青少年。
Pediatr Infect Dis J. 2021 Dec 1;40(12):e472-e474. doi: 10.1097/INF.0000000000003360.
3
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report.免疫功能低下患者持续性 SARS-CoV-2 感染治疗过程中雷米昔韦耐药突变的从头出现：一例病例报告。
Nat Commun. 2022 Mar 17;13(1):1547. doi: 10.1038/s41467-022-29104-y.
4
Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report.瑞德西韦治疗无体液免疫的 COVID-19：一例报告。
Nat Commun. 2020 Dec 14;11(1):6385. doi: 10.1038/s41467-020-19761-2.
5
Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir.严重免疫功能低下患者接受多疗程瑞德西韦治疗后，SARS-CoV-2 持续复制。
Int J Infect Dis. 2021 Mar;104:379-381. doi: 10.1016/j.ijid.2020.12.050. Epub 2020 Dec 21.
6
Safety of casirivimab/imdevimab administration in a SARS-CoV-2 positive maintenance dialysis patient in Japan.日本 SARS-CoV-2 阳性维持性透析患者使用卡司瑞韦单抗/伊德韦单抗的安全性。
CEN Case Rep. 2022 Aug;11(3):328-332. doi: 10.1007/s13730-021-00671-1. Epub 2022 Jan 9.
7
Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.成功使用 casirivimab/imdevimab 抗刺突单克隆抗体增强了一名接受抗 CD20 治疗的难治性 COVID-19 女性的中和抗体。
J Infect Chemother. 2022 Jul;28(7):991-994. doi: 10.1016/j.jiac.2022.03.002. Epub 2022 Mar 23.
8
Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge.奥密克戎 BA.1 流行期间，高风险轻至中度 COVID-19 门诊患者使用瑞德西韦和索特罗维单抗的可比结局。
Sci Rep. 2024 Mar 5;14(1):5430. doi: 10.1038/s41598-024-56195-y.
9
Clinical Efficacy of Imdevimab/Casirivimab for Persistent Omicron SARS-CoV-2 Infection in Patients with Hematological Malignancies.西美瑞韦单抗/罗米司韦单抗治疗血液恶性肿瘤患者持续性奥密克戎 SARS-CoV-2 感染的临床疗效。
Intern Med. 2024 Aug 15;63(16):2283-2287. doi: 10.2169/internalmedicine.2900-23. Epub 2024 Jan 2.
10
Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.继发抗体缺陷患者中持续的 SARS-CoV-2 感染：使用 casirivimab 和 imdevimab（REGN-COV2）单克隆抗体联合治疗后成功清除。
Ann Clin Microbiol Antimicrob. 2021 Dec 30;20(1):85. doi: 10.1186/s12941-021-00491-2.

引用本文的文献

1
Rapid Response to Remdesivir in Hospitalised COVID-19 Patients: A Propensity Score Weighted Multicentre Cohort Study.住院COVID-19患者对瑞德西韦的快速反应：一项倾向评分加权多中心队列研究。
Infect Dis Ther. 2023 Oct;12(10):2471-2484. doi: 10.1007/s40121-023-00874-2. Epub 2023 Oct 6.
2
[Repeatedly re-detectable positive for SARS-CoV-2 by RT-PCR in the immunosuppressive therapy of a patient: a case report and literature review].[一名患者免疫抑制治疗期间SARS-CoV-2经逆转录聚合酶链反应多次检测呈阳性：病例报告及文献综述]
Zhonghua Xue Ye Xue Za Zhi. 2023 Jun 14;44(6):520-522. doi: 10.3760/cma.j.issn.0253-2727.2023.06.016.
3

本文引用的文献

1
COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses.COVID-19 免疫特征表明，尽管抗体反应下降，但抗病毒 T 细胞功能仍保持稳定。
Immunity. 2021 Feb 9;54(2):340-354.e6. doi: 10.1016/j.immuni.2021.01.008.
2
A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma.一名患有X连锁无丙种球蛋白血症且感染新冠病毒的患者接受瑞德西韦和康复期血浆治疗。
J Clin Immunol. 2021 Jul;41(5):923-925. doi: 10.1007/s10875-021-00983-y. Epub 2021 Feb 6.
3
SARS-CoV-2 evolution during treatment of chronic infection.
SARS-CoV-2 Infection and Response to COVID-19 Vaccination in Patients With Primary Immunodeficiencies.
原发性免疫缺陷病患者的 SARS-CoV-2 感染和对 COVID-19 疫苗接种的反应。
J Infect Dis. 2023 Aug 4;228(Suppl 1):S24-S33. doi: 10.1093/infdis/jiad145.
4
COVID-19 Pneumonia with Migratory Pattern in Agammaglobulinemic Patients: A Report of Two Cases and Review of Literature.免疫球蛋白缺乏症患者的 COVID-19 肺炎伴游走性表现：两例病例报告及文献复习。
Tomography. 2023 Apr 23;9(3):894-900. doi: 10.3390/tomography9030073.
5
COVID-19 relapse associated with SARS-CoV-2 evasion from CD4 T-cell recognition in an agammaglobulinemia patient.一名无丙种球蛋白血症患者中，新冠病毒感染复发与严重急性呼吸综合征冠状病毒2逃避CD4 T细胞识别有关。
iScience. 2023 May 19;26(5):106685. doi: 10.1016/j.isci.2023.106685. Epub 2023 Apr 20.
6
Case report: Clinical course and treatment of SARS-CoV-2 in a pediatric CAR-T cell recipient with persistent hypogammaglobulinemia.病例报告：一名患有持续性低丙种球蛋白血症的儿科CAR-T细胞接受者感染新型冠状病毒2的临床病程及治疗情况
Front Pediatr. 2023 Mar 10;11:1076686. doi: 10.3389/fped.2023.1076686. eCollection 2023.
7
Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity.严重急性呼吸综合征冠状病毒 2 感染和 COVID-19 对先天性免疫缺陷病患者的影响。
J Allergy Clin Immunol. 2023 Apr;151(4):818-831. doi: 10.1016/j.jaci.2022.11.010. Epub 2022 Dec 13.
8
Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy.瑞德西韦可降低患有活动性恶性肿瘤的COVID-19患者的死亡率。
Cancers (Basel). 2022 Sep 28;14(19):4720. doi: 10.3390/cancers14194720.
9
COVID-19 in patients with B cell immune deficiency.B 细胞免疫缺陷患者的 COVID-19 。
J Immunol Methods. 2022 Nov;510:113351. doi: 10.1016/j.jim.2022.113351. Epub 2022 Sep 7.
10
COVID-19-related health outcomes in people with primary immunodeficiency: A systematic review.原发性免疫缺陷患者的 COVID-19 相关健康结局：系统评价。
Clin Immunol. 2022 Oct;243:109097. doi: 10.1016/j.clim.2022.109097. Epub 2022 Aug 13.
慢性感染治疗过程中 SARS-CoV-2 的进化。
Nature. 2021 Apr;592(7853):277-282. doi: 10.1038/s41586-021-03291-y. Epub 2021 Feb 5.
4
Burton's Agammaglobulinemia and COVID-19.伯顿无丙种球蛋白血症与新型冠状病毒肺炎
Cureus. 2020 Nov 25;12(11):e11701. doi: 10.7759/cureus.11701.
5
Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir.严重免疫功能低下患者接受多疗程瑞德西韦治疗后，SARS-CoV-2 持续复制。
Int J Infect Dis. 2021 Mar;104:379-381. doi: 10.1016/j.ijid.2020.12.050. Epub 2020 Dec 21.
6
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.REGN-COV2，一种中和抗体鸡尾酒疗法，用于治疗门诊新冠患者。
N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17.
7
Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report.瑞德西韦治疗无体液免疫的 COVID-19：一例报告。
Nat Commun. 2020 Dec 14;11(1):6385. doi: 10.1038/s41467-020-19761-2.
8
Atypical course of COVID-19 in patient with Bruton agammaglobulinemia.患有布鲁顿无丙种球蛋白血症的COVID-19患者的非典型病程。
J Infect Dev Ctries. 2020 Nov 30;14(11):1248-1251. doi: 10.3855/jidc.13840.
9
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host.严重急性呼吸综合征冠状病毒2型在免疫功能低下宿主中的持续存在与演变
N Engl J Med. 2020 Dec 3;383(23):2291-2293. doi: 10.1056/NEJMc2031364. Epub 2020 Nov 11.
10
Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma.三名因新冠病毒疾病住院治疗的X连锁无丙种球蛋白血症患者接受恢复期血浆治疗后病情好转。
J Allergy Clin Immunol Pract. 2020 Nov-Dec;8(10):3594-3596.e3. doi: 10.1016/j.jaip.2020.08.059. Epub 2020 Sep 15.